<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35274">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02055820</url>
  </required_header>
  <id_info>
    <org_study_id>GO27878</org_study_id>
    <nct_id>NCT02055820</nct_id>
  </id_info>
  <brief_title>A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase Ib, Open-Label Study Evaluating The Safety And Pharmacokinetics Of GDC-0199 (ABT-199) In Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine And Prednisone (Chop) In Patients With B-Cell Non-Hodgkins Lymphoma (NHL) and DLBCL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, dose-finding study of GDC-0199 administered orally in
      combination with MabThera/Rituxan (R) or obinutuzumab (G) and standard doses of
      cyclophosphamide, doxorubicin, vincristine and oral prednisone (CHOP) in patients with
      Non-Hodgkins Lymphoma (NHL). Patients will be randomized to one of two treatment arms of
      GDC-0199 in combination with R-CHOP and G-CHOP. The study will consist of two stages, a
      dose-finding stage and an expansion stage. The maximum tolerated dose (MTD) of GDC-0199 in
      combination with R-CHOP and G-CHOP will be determined during the dose-finding stage.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety: Incidence of dose-limiting toxicities</measure>
    <time_frame>Approximately 9 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete response (CR) defined by PET/CT scan and bone marrow examination</measure>
    <time_frame>Approximately 9 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative dose intensity</measure>
    <time_frame>Approximately 9 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response (partial or complete response) rate</measure>
    <time_frame>Approximately 9 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration, defined as time from first documented response until relapse or death.</measure>
    <time_frame>Approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>Approximately 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR defined by CT scan and bone marrow examination</measure>
    <time_frame>Approximately 9 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: plasma concentration-time profile of GDC-0199</measure>
    <time_frame>Approximately 9 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">248</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>GDC-0199 + R-CHOP Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GDC-0199 + G-CHOP Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>obinutuzumab</intervention_name>
    <description>Obinutuzumab 1000 mg on Days 1, 8, 15, Cycle 1. Following cycles on Day 1.</description>
    <arm_group_label>GDC-0199 + G-CHOP Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHOP</intervention_name>
    <description>Standard doses of cyclophosphamide, doxorubicin, vincristine and oral prednisone (CHOP)</description>
    <arm_group_label>GDC-0199 + R-CHOP Arm</arm_group_label>
    <arm_group_label>GDC-0199 + G-CHOP Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0199</intervention_name>
    <description>Daily doses of GDC-0199</description>
    <arm_group_label>GDC-0199 + R-CHOP Arm</arm_group_label>
    <arm_group_label>GDC-0199 + G-CHOP Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab [MabThera/Rituxan]</intervention_name>
    <description>Rituximab 375 mg/m2 on Day 1 of every cycle</description>
    <arm_group_label>GDC-0199 + R-CHOP Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General Inclusion Criteria:

          -  Patients, age &gt; = 18 years

          -  At least one bi-dimensionally measurable lesion defined as &gt; 1.5 cm in its longest
             dimension

          -  Ability and willingness to comply with the study protocol procedures

          -  Confirmed availability of archival or freshly biopsied tumor tissue prior to study
             enrollment

          -  ECOG performance status of 0, 1 or 2

          -  Adequate hematologic function

          -  For female patients of childbearing potential, agreement to use highly effective
             forms of contraception

        Dose Escalation Portion of the Study:

          -  Patients must have histologically confirmed B-cell non-Hodgkin's Lymphoma (NHL)

          -  Patients must have never received previous R-CHOP treatment

          -  Any relapsed/refractory patients that are enrolled during the dose escalation should
             have received only a single previous treatment regimen

        Expansion Portion of the Study:

          -  Patients must have previously-untreated diffuse large, B-cell lymphoma

          -  International prognostic index (IP) score must be 2-5

        Exclusion Criteria:

        General Exclusion Criteria:

          -  Contraindication to receive any of the individual components of CHOP, rituximab or
             obinutuzumab

          -  Primary CNS lymphoma

          -  Vaccination with live vaccines within 28 days prior to randomization

          -  History of other malignancy that could affect compliance with the protocol or
             interpretation of results

          -  Evidence of significant, concomitant disease or illness

          -  Use of CYP3A inhibitors or inducers within 7 days of the first dose of GDC-0199

          -  Requires use of Warfarin

          -  Recent major surgery

          -  Women must not be pregnant or breastfeeding

        Dose Escalation Portion of the Study:

          -  Prior anthracycline therapy

          -  Chemotherapy or other investigational therapy within 5 half-lives of a biologic agent
             with minimum of 28 days prior to the start of Cycle 1

          -  Histologically confirmed mantle cell lymphoma (MCL) or small lymphocytic lymphoma
             (SLL)

        Expansion Portion of the Study:

          -  Patients with transformed lymphoma

          -  Prior therapy for non-Hodgkins Lymphoma (NHL)

          -  Current Grade &gt; 1 peripheral neuropathy

          -  Ongoing therapy with calcium channel entry blocker drugs or therapy within 30 days of
             C1D1

          -  Prior radiotherapy to the mediastinal/pericardial region
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GO27878 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Utrecht</city>
        <zip>3584 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 26, 2014</lastchanged_date>
  <firstreceived_date>February 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
